Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05462470

Enrollment

255

Registered

2022-07-18

Start date

2008-01-01

Completion date

2022-04-30

Last updated

2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Liver Metastases

Brief summary

For patients with initially unresectable colorectal liver metastasis (IU-CRLM) receiving effective conversion therapy, disease relapse after conversion hepatectomy is common due to the extensive tumor load. Yet, few studies have focused on the assessment and management of relapse after conversion hepatectomy for IU-CRLM. This study aimed to investigate the impact of surgical management for relapse after conversion hepatectomy in IU-CRLM.

Interventions

PROCEDURERepeat Liver Surgery

repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)

PROCEDURENon-Repeat Liver Surgery

Systemic palliative chemotherapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* initially unresectable colorectal liver metastasis (IU-CRLM) * received conversion therapy * underwent conversion hepatectomy

Exclusion criteria

* the histologic type of CRLM was not called adenocarcinoma * uncontrollable extrahepatic metastases, such as peritoneal, bone, brain metastasis * history of previous hepatectomy * the primary tumor was not resected or palliative resection * R1 or R2 liver resection

Design outcomes

Primary

Measure	Time frame	Description
overall survival	5 years	Overall survival after the first resection of liver metastatic lesions

Secondary

Measure	Time frame	Description
first relapse free survival	5 years	relapse free survival after the first resection of liver metastatic lesions
second relapse free survival	5 years	relapse free survival after the repeat liver surgery of liver metastatic lesions
Severe complication rate after resection of primary and metastatic lesions	30 days after surgery	Grade of III-V complication rate according to Clavien-Dindo

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026